Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...
Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD ...
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic ...
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative ...
− All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, ...
TURIN, Italy--(BUSINESS WIRE)--Go Reply, a leading Google Cloud Premier Partner, together with Sprint Reply, the Reply Group’s expert in strategic consulting and digital transformation, has developed ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
The global CRO market is projected to hit almost $63 billion by the end of the decade, growing an average of 7.39% annually from 2025 to 2030, according to a new report from Irish-based market ...
A new international online survey published in the Journal of Affective Disorders gives voice to the lived experiences of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback